Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Aug 10, 2016
Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference

Aug 8, 2016
Arbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology


View all »Events & Presentations

Aug 16, 2016
2016 Wedbush PacGrow Healthcare Conference

Jul 17, 2016
2016 Controlled Release Society Conference